{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:30:42Z","timestamp":1786350642151,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Northeastern University USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Folia Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Beta-lactamase production by\n                    <jats:italic>Burkholderia cepacia<\/jats:italic>\n                    complex (Bcc) leads to beta-lactam resistance and worsens patient prognosis. This study describes the activity of aztreonam, a monobactam, in combination with avibactam, a beta-lactamase inhibitor, against Bcc isolates. Broth microdilution and time-kill assays were conducted for planktonic cells. Additionally, broth microdilution was repeated using media supplemented with 5% and 10% bovine serum albumin to evaluate its impact on MICs. The effects of aztreonam\/avibactam on biofilm formation and the metabolic activity of mature biofilms were determined in all biofilm-positive isolates. Additionally, the biofilm matrix of selected strains was analyzed in terms of viable bacterial count, total protein content, and extracellular DNA (eDNA) concentration, and the biofilm architecture was visualized using scanning electron microscopy (SEM). All the strains were determined to be resistant to aztreonam, and the MIC\n                    <jats:sub>50<\/jats:sub>\n                    and MIC\n                    <jats:sub>90<\/jats:sub>\n                    of aztreonam\/avibactam were found to be 4\/4\u00a0mg\/L and 8\/4\u00a0mg\/L, respectively. Aztreonam\/avibactam exhibited activity against planktonic form of Bcc, and decreased the aztreonam MIC values. Serum albumin activity was insignificant at low doses but affected the MIC more at high doses. Moderate to strong biofilm formation was observed in 25 of the 29 isolates, and aztreonam\/avibactam showed strain- and concentration-dependent activity against Bcc biofilm formation and mature biofilms. The combination also reduced biofilm matrix components such as total protein and eDNA, and some strain-specific effects were observed at sub-inhibitory concentrations. These findings support the potential use of aztreonam\/avibactam as a therapeutic option against Bcc infections by targeting both planktonic bacteria and key components of biofilm matrix.\n                  <\/jats:p>","DOI":"10.1007\/s12223-026-01569-0","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:06:56Z","timestamp":1786349216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the antimicrobial and antibiofilm activities of aztreonam-avibactam against the Burkholderia cepacia complex"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-7225","authenticated-orcid":false,"given":"Ozlem","family":"Oyardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-3168","authenticated-orcid":false,"given":"Damla Damar","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7335-1213","authenticated-orcid":false,"given":"Taylan","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3439-9158","authenticated-orcid":false,"given":"Burak","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"1569_CR1","doi-asserted-by":"publisher","first-page":"106372","DOI":"10.1016\/j.ijantimicag.2021.106372","volume":"58","author":"A Aiyer","year":"2021","unstructured":"Aiyer A, Manoharan A, Paino D, Farrell J, Whiteley GS, Kriel FH, Glasbey TO, Manos J, Das T (2021) Disruption of biofilms and killing of Burkholderia cenocepacia from cystic fibrosis lung using an antioxidant-antibiotic combination therapy. Int J Antimicrob Agents 58:106372. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106372","journal-title":"Int J Antimicrob Agents"},{"issue":"136","key":"1569_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/apm.12099","volume":"121","author":"T Bjarnsholt","year":"2013","unstructured":"Bjarnsholt T (2013) The role of bacterial biofilms in chronic infections. APMIS Suppl 121(136):1\u201351. https:\/\/doi.org\/10.1111\/apm.12099","journal-title":"APMIS Suppl"},{"key":"1569_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrmicro.2016.34","volume":"14","author":"A Brauner","year":"2016","unstructured":"Brauner A, Fridman O, Gefen O, Balaban NQ (2016) Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol 14:320\u2013330. https:\/\/doi.org\/10.1038\/nrmicro.2016.34","journal-title":"Nat Rev Microbiol"},{"key":"1569_CR5","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1128\/jcm.42.7.3052-3058.2004","volume":"42","author":"MV Cunha","year":"2004","unstructured":"Cunha MV, Sousa SA, Leit\u00e3o JH, Moreira LM, Videira PA, S\u00e1-Correia I (2004) Studies on the involvement of the exopolysaccharide produced by cystic fibrosis-associated isolates of the Burkholderia cepacia complex in biofilm formation and in persistence of respiratory infections. J Clin Microbiol 42:3052\u20133058. https:\/\/doi.org\/10.1128\/jcm.42.7.3052-3058.2004","journal-title":"J Clin Microbiol"},{"key":"1569_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/1120009X.2020.1819702","volume":"33","author":"D Damar-Celik","year":"2021","unstructured":"Damar-Celik D, Mataraci-Kara E, Savage PB, Ozbek-Celik B (2021) Antibacterial and antibiofilm activities of ceragenins against Achromobacter species isolated from cystic fibrosis patients. J Chemother 33:216\u2013227. https:\/\/doi.org\/10.1080\/1120009X.2020.1819702","journal-title":"J Chemother"},{"key":"1569_CR7","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1186\/s12879-024-09790-3","volume":"24","author":"R Elawady","year":"2024","unstructured":"Elawady R, Aboulela AG, Gaballah A, Ghazal AA, Amer AN (2024) Antimicrobial Sub-MIC induces Staphylococcus aureus biofilm formation without affecting the bacterial count. BMC Infect Dis 24:1065. https:\/\/doi.org\/10.1186\/s12879-024-09790-3","journal-title":"BMC Infect Dis"},{"key":"1569_CR8","unstructured":"EUCAST (2023) Expected Resistant Phenotypes Version 1.2 (January 2023). European Committee on Antimicrobial Susceptibility Testing"},{"key":"1569_CR9","volume-title":"EUCAST reading guide for broth microdilution. Version 5.0. January 2024","author":"EUCAST","year":"2024","unstructured":"EUCAST (2024) EUCAST reading guide for broth microdilution. Version 5.0. January 2024. EUCAST, V\u00e4xj\u00f6, Sweden"},{"key":"1569_CR4","unstructured":"European Commission. Emblaveo (aztreonam\/avibactam): Union Register of medicinal products for human use. European Commission (2024) Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1808.htm"},{"key":"1569_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13756-016-0142-3","volume":"5","author":"A Everaert","year":"2016","unstructured":"Everaert A, Coenye T (2016) Effect of \u03b2-Lactamase inhibitors on in vitro activity of \u03b2-Lactam antibiotics against Burkholderia cepacia complex species. Antimicrob Resist Infect Control 5:44. https:\/\/doi.org\/10.1186\/s13756-016-0142-3","journal-title":"Antimicrob Resist Infect Control"},{"key":"1569_CR11","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1089\/mdr.2019.0102","volume":"26","author":"V Gautam","year":"2020","unstructured":"Gautam V, Kumar S, Patil PP, Meletiadis J, Patil PB, Mouton JW, Sharma M, Daswal A, Singhal L, Ray P, Singh M (2020) Exploring the interplay of resistance nodulation division efflux pumps, AmpC and OprD in antimicrobial resistance of Burkholderia cepacia complex in clinical isolates. Microb Drug Resist 26:1144\u20131152. https:\/\/doi.org\/10.1089\/mdr.2019.0102","journal-title":"Microb Drug Resist"},{"key":"1569_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41429-020-0299-0","volume":"73","author":"M Hacioglu","year":"2020","unstructured":"Hacioglu M, Oyardi O, Bozkurt-Guzel C, Savage PB (2020) Antibiofilm activities of ceragenins and antimicrobial peptides against fungal-bacterial mono and multispecies biofilms. J Antibiot (Tokyo) 73:455\u2013462. https:\/\/doi.org\/10.1038\/s41429-020-0299-0","journal-title":"J Antibiot (Tokyo)"},{"key":"1569_CR13","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1038\/s41467-023-40494-5","volume":"14","author":"AM Hogan","year":"2023","unstructured":"Hogan AM, Rahman ASMZ, Motnenko A, Natarajan A, Maydaniuk DT, Le\u00f3n B, Batun Z, Palacios A, Bosch A, Cardona ST (2023) Profiling cell envelope-antibiotic interactions reveals vulnerabilities to \u03b2-lactams in a multidrug-resistant bacterium. Nat Commun 14:4815. https:\/\/doi.org\/10.1038\/s41467-023-40494-5","journal-title":"Nat Commun"},{"key":"1569_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/apm.12689","volume":"125","author":"N H\u00f8iby","year":"2017","unstructured":"H\u00f8iby N, Bjarnsholt T, Moser C, Jensen P\u00d8, Kolpen M, Qvist T, Aan\u00e6s K, Pressler T, Skov M, Ciofu O (2017) Diagnosis of biofilm infections in cystic fibrosis patients. Apmis 125:339\u2013343. https:\/\/doi.org\/10.1111\/apm.12689","journal-title":"Apmis"},{"key":"1569_CR15","doi-asserted-by":"publisher","first-page":"dlae006","DOI":"10.1093\/jacamr\/dlae006","volume":"6","author":"YS Huang","year":"2024","unstructured":"Huang YS, Chuang YC, Chen PY, Chou PC, Wang JT (2024) In vitro activity of cefiderocol and comparator antibiotics against multidrug-resistant non-fermenting Gram-negative bacilli. JAC Antimicrob Resist 6:dlae006. https:\/\/doi.org\/10.1093\/jacamr\/dlae006","journal-title":"JAC Antimicrob Resist"},{"key":"1569_CR16","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.ijregi.2024.03.010","volume":"11","author":"T Ibrahim","year":"2024","unstructured":"Ibrahim T, Abdallah TA, Abdallah A, Qazi R, Alimam A, Mohammad H, Eltayeb F, Daghfal J, Ali M, Abdel Hadi H (2024) Epidemiology, microbiological, clinical characteristics, and outcome of Burkholderia cepacia complex infections in non-cystic fibrosis adult patients from Qatar. IJID Reg 11:100355. https:\/\/doi.org\/10.1016\/j.ijregi.2024.03.010","journal-title":"IJID Reg"},{"key":"1569_CR17","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1128\/AAC.02894-14","volume":"58","author":"TR Keepers","year":"2014","unstructured":"Keepers TR, Gomez M, Celeri C, Nichols WW, Krause KM (2014) Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 58:5297\u20135305. https:\/\/doi.org\/10.1128\/AAC.02894-14","journal-title":"Antimicrob Agents Chemother"},{"key":"1569_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1099\/jmm.0.000458","volume":"66","author":"DTD Kenna","year":"2017","unstructured":"Kenna DTD, Lilley D, Coward A, Martin K, Perry C, Pike R, Hill R, Turton JF (2017) Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients. J Med Microbiol 66:490\u2013501. https:\/\/doi.org\/10.1099\/jmm.0.000458","journal-title":"J Med Microbiol"},{"key":"1569_CR19","doi-asserted-by":"publisher","first-page":"107601","DOI":"10.1016\/j.jmgm.2020.107601","volume":"98","author":"S Ketrat","year":"2020","unstructured":"Ketrat S, Japrung D, Pongprayoon P (2020) Exploring how structural and dynamic properties of bovine and canine serum albumins differ from human serum albumin. J Mol Graph Model 98:107601. https:\/\/doi.org\/10.1016\/j.jmgm.2020.107601","journal-title":"J Mol Graph Model"},{"key":"1569_CR20","doi-asserted-by":"publisher","first-page":"100156","DOI":"10.1016\/j.bioflm.2023.100156","volume":"6","author":"J Liu","year":"2023","unstructured":"Liu J, Huang T, Xu Z, Mao Y, Soteyome T, Liu G, Qu C, Yuan L, Ma Q, Zhou F, Seneviratne G (2023) Sub-MIC streptomycin and tetracycline enhanced Staphylococcus aureus Guangzhou-SAU749 biofilm formation, an in-depth study on transcriptomics. Biofilm 6:100156. https:\/\/doi.org\/10.1016\/j.bioflm.2023.100156","journal-title":"Biofilm"},{"key":"1569_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jcf.2013.07.004","volume":"13","author":"A-S Messiaen","year":"2014","unstructured":"Messiaen A-S, Nelis H, Coenye T (2014) Investigating the role of matrix components in protection of Burkholderia cepacia complex biofilms against tobramycin. J Cyst Fibros 13:56\u201362. https:\/\/doi.org\/10.1016\/j.jcf.2013.07.004","journal-title":"J Cyst Fibros"},{"key":"1569_CR22","doi-asserted-by":"publisher","first-page":"ftv069","DOI":"10.1093\/femspd\/ftv069","volume":"73","author":"MP Murphy","year":"2015","unstructured":"Murphy MP, Caraher E (2015) Residence in biofilms allows Burkholderia cepacia complex (Bcc) bacteria to evade the antimicrobial activities of neutrophil-like dHL60 cells. Pathog Dis 73:ftv069. https:\/\/doi.org\/10.1093\/femspd\/ftv069","journal-title":"Pathog Dis"},{"key":"1569_CR23","unstructured":"NCCLS (1999) Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. In, Wayne, PA, USA"},{"key":"1569_CR24","doi-asserted-by":"publisher","first-page":"785573","DOI":"10.3389\/fmicb.2021.785573","volume":"12","author":"TK Nguyen","year":"2021","unstructured":"Nguyen TK, Peyrusson F, Siala W, Pham NH, Nguyen HA, Tulkens PM, Van Bambeke F (2021) Activity of moxifloxacin against biofilms formed by clinical isolates Staphylococcus aureus differing by their resistant or persister character to fluoroquinolones. Front Microbiol 12:785573. https:\/\/doi.org\/10.3389\/fmicb.2021.785573","journal-title":"Front Microbiol"},{"issue":"47","key":"1569_CR25","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.3791\/2437","volume":"30","author":"GA O\u2019Toole","year":"2011","unstructured":"O\u2019Toole GA (2011) Microtiter dish biofilm formation assay. J Vis Exp 30(47):2437. https:\/\/doi.org\/10.3791\/2437","journal-title":"J Vis Exp"},{"key":"1569_CR26","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1128\/IAI.00318-08","volume":"76","author":"J Overhage","year":"2008","unstructured":"Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE (2008) Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76:4176\u20134182. https:\/\/doi.org\/10.1128\/IAI.00318-08","journal-title":"Infect Immun"},{"key":"1569_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/jac\/dkaa434","volume":"76","author":"O Oyardi","year":"2021","unstructured":"Oyardi O, Savage PB, Erturan Z, Bozkurt-Guzel C (2021) In vitro assessment of CSA-131 and CSA-131 poloxamer form for the treatment of Stenotrophomonas maltophilia infections in cystic fibrosis. J Antimicrob Chemother 76:443\u2013450. https:\/\/doi.org\/10.1093\/jac\/dkaa434","journal-title":"J Antimicrob Chemother"},{"key":"1569_CR28","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","volume":"3","author":"KM Papp-Wallace","year":"2017","unstructured":"Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, Falleni M, Tosi D, Borghi E, Winkler ML, Wilson BM, LiPuma JJ, Nukaga M, Bonomo RA (2017) Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis 3:502\u2013511. https:\/\/doi.org\/10.1021\/acsinfecdis.7b00020","journal-title":"ACS Infect Dis"},{"key":"1569_CR29","doi-asserted-by":"publisher","first-page":"e01930","DOI":"10.1128\/aac.01930-20","volume":"65","author":"KM Papp-Wallace","year":"2021","unstructured":"Papp-Wallace KM, Shapiro AB, Becka SA, Zeiser ET, LiPuma JJ, Lane DJ, Panchal RG, Mueller JP, O\u2019Donnell JP, Miller AA (2021) In vitro antibacterial activity and in vivo efficacy of sulbactam-durlobactam against pathogenic Burkholderia species. Antimicrob Agents Chemother 65:e01930\u2013e01920. https:\/\/doi.org\/10.1128\/aac.01930-20","journal-title":"Antimicrob Agents Chemother"},{"key":"1569_CR30","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/jac\/dkw231","volume":"71","author":"C Ramsey","year":"2016","unstructured":"Ramsey C, MacGowan AP (2016) A review of the pharmacokinetics and pharmacodynamics of aztreonam. J Antimicrob Chemother 71:2704\u20132712. https:\/\/doi.org\/10.1093\/jac\/dkw231","journal-title":"J Antimicrob Chemother"},{"key":"1569_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.mib.2018.07.006","volume":"45","author":"MR Ranieri","year":"2018","unstructured":"Ranieri MR, Whitchurch CB, Burrows LL (2018) Mechanisms of biofilm stimulation by subinhibitory concentrations of antimicrobials. Curr Opin Microbiol 45:164\u2013169. https:\/\/doi.org\/10.1016\/j.mib.2018.07.006","journal-title":"Curr Opin Microbiol"},{"key":"1569_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drup.2016.07.003","volume":"28","author":"KA Rhodes","year":"2016","unstructured":"Rhodes KA, Schweizer HP (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82\u201390. https:\/\/doi.org\/10.1016\/j.drup.2016.07.003","journal-title":"Drug Resist Updat"},{"issue":"22","key":"1569_CR33","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.3390\/molecules27227858","volume":"27","author":"AA Sabour","year":"2022","unstructured":"Sabour AA, Khan A, Alhuzani MR (2022) Insight into the interaction mechanism of HSA with aztreonam: A multispectroscopic and computational approach. Molecules 27(22):7858. https:\/\/doi.org\/10.3390\/molecules27227858","journal-title":"Molecules"},{"key":"1569_CR36","doi-asserted-by":"publisher","unstructured":"Sader HS, Shortridge D, Ryan Arends SJ, Carvalhaes CG, Mendes RE, Castanheira M (2022) Antimicrobial activity of aztreonam-avibactam against a large collection of Stenotrophomonas maltophilia and Burkholderia cepacia species complex causing infections in United States (US) medical centers (2016\u20132021). Open Forum Infect Dis. 2022;9(Suppl 2):ofac492.1314. https:\/\/doi.org\/10.1093\/ofid\/ofac492.1314","DOI":"10.1093\/ofid\/ofac492.1314"},{"key":"1569_CR34","doi-asserted-by":"publisher","first-page":"107113","DOI":"10.1016\/j.ijantimicag.2024.107113","volume":"63","author":"HS Sader","year":"2024","unstructured":"Sader HS, Carvalhaes CG, Kimbrough JH, Mendes RE, Castanheira M (2024a) Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020\u20132022). Int J Antimicrob Agents 63:107113. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107113","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1569_CR35","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/antibiotics13060564","volume":"13","author":"HS Sader","year":"2024","unstructured":"Sader HS, Mendes RE, Kimbrough JH, Hubler CM, Castanheira M (2024b) Activity of aztreonam\/avibactam and recently approved \u03b2-lactamase inhibitor combinations against Enterobacterales and Pseudomonas aeruginosa from intensive care unit and non-intensive care unit patients. Antibiot (Basel) 13(6):564. https:\/\/doi.org\/10.3390\/antibiotics13060564","journal-title":"Antibiot (Basel)"},{"key":"1569_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/mdr.2021.0353","volume":"28","author":"F Schaumburg","year":"2022","unstructured":"Schaumburg F, Idelevich EA, Mellmann A, Kahl BC (2022) Susceptibility of Burkholderia cepacia Complex to Ceftazidime\/Avibactam and Standard Drugs of Treatment for Cystic Fibrosis Patients. Microb Drug Resist 28:545\u2013550. https:\/\/doi.org\/10.1089\/mdr.2021.0353","journal-title":"Microb Drug Resist"},{"key":"1569_CR38","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1128\/iai.70.8.4547-4555.2002","volume":"70","author":"U Schwab","year":"2002","unstructured":"Schwab U, Leigh M, Ribeiro C, Yankaskas J, Burns K, Gilligan P, Sokol P, Boucher R (2002) Patterns of epithelial cell invasion by different species of the Burkholderia cepacia complex in well-differentiated human airway epithelia. Infect Immun 70:4547\u20134555. https:\/\/doi.org\/10.1128\/iai.70.8.4547-4555.2002","journal-title":"Infect Immun"},{"key":"1569_CR39","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1017\/ice.2020.184","volume":"41","author":"RZ Shaban","year":"2020","unstructured":"Shaban RZ, Sotomayor-Castillo C, Nahidi S, Li C, Macbeth D, Mitchell BG, Russo PL (2020) Global burden, point sources, and outbreak management of healthcare-associated Burkholderia cepacia infections: An integrative review. Infect Control Hosp Epidemiol 41:777\u2013783. https:\/\/doi.org\/10.1017\/ice.2020.184","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1569_CR40","doi-asserted-by":"publisher","first-page":"e0000624","DOI":"10.1128\/jb.00006-24","volume":"206","author":"DK Sharma","year":"2024","unstructured":"Sharma DK, Rajpurohit YS (2024) Multitasking functions of bacterial extracellular DNA in biofilms. J Bacteriol 206:e0000624. https:\/\/doi.org\/10.1128\/jb.00006-24","journal-title":"J Bacteriol"},{"key":"1569_CR41","doi-asserted-by":"publisher","first-page":"e00590","DOI":"10.1128\/AAC.00590-18","volume":"62","author":"A Van Dalem","year":"2018","unstructured":"Van Dalem A, Herpol M, Echahidi F, Peeters C, Wybo I, De Wachter E, Vandamme P, Pi\u00e9rard D (2018) In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam. Antimicrob Agents Chemother 62:e00590\u2013e00518. https:\/\/doi.org\/10.1128\/AAC.00590-18","journal-title":"Antimicrob Agents Chemother"},{"key":"1569_CR42","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s00284-016-1081-1","volume":"73","author":"Z Xu","year":"2016","unstructured":"Xu Z, Liang Y, Lin S, Chen D, Li B, Li L, Deng Y (2016) Crystal violet and XTT assays on Staphylococcus aureus biofilm quantification. Curr Microbiol 73:474\u2013482. https:\/\/doi.org\/10.1007\/s00284-016-1081-1","journal-title":"Curr Microbiol"},{"key":"1569_CR43","doi-asserted-by":"publisher","first-page":"e00181","DOI":"10.1128\/jcm.00181-19","volume":"57","author":"ET Zeiser","year":"2019","unstructured":"Zeiser ET, Becka SA, Wilson BM, Barnes MD, LiPuma JJ, Papp-Wallace KM (2019) Switching Partners: Piperacillin-Avibactam is a highly potent combination against multidrug-resistant Burkholderia cepacia complex and Burkholderia gladioli cystic fibrosis isolates. J Clin Microbiol 57:e00181\u2013e00119. https:\/\/doi.org\/10.1128\/jcm.00181-19","journal-title":"J Clin Microbiol"},{"key":"1569_CR44","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1128\/aac.01433-10","volume":"55","author":"MA Zeitlinger","year":"2011","unstructured":"Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U (2011) Protein binding: do we ever learn? Antimicrob Agents Chemother 55:3067\u20133074. https:\/\/doi.org\/10.1128\/aac.01433-10","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Folia Microbiologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12223-026-01569-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12223-026-01569-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12223-026-01569-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:06:58Z","timestamp":1786349218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12223-026-01569-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":44,"alternative-id":["1569"],"URL":"https:\/\/doi.org\/10.1007\/s12223-026-01569-0","relation":{},"ISSN":["0015-5632","1874-9356"],"issn-type":[{"value":"0015-5632","type":"print"},{"value":"1874-9356","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Was obtained from the Ethics Committee of Marmara University, Institute of Health Sciences, T\u00fcrkiye (19.11.2024\u2013106).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}